Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii Isolates Among Intensive Care Unit Patients and Environment

References

• Ripabelli G, Sammarco ML, Scutella M, Felice V, Tamburro M. Carbapenem-resistant kpc- and tem-producing Escherichia coli st131 isolated from a hospitalized patient with urinary tract infection: first isolation in Molise region, central Italy, July 2018. Microb Drug Resist. 2020;26(1):38–45. doi:10.1089/mdr.2019.0085
   PubMed Web of Science ®Google Scholar
• Sarshar M, Behzadi P, Scribano D, Palamara AT, Ambrosi C. Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens. 2021;10(4):387. doi:10.3390/pathogens10040387
   PubMed Web of Science ®Google Scholar
• Hu H, Zhang Y, Zhang P, et al. Bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing p. Aeruginosa sequence type 463, associated with high mortality rates in China: a retrospective cohort study. Front Cell Infect Microbiol. 2021;11:756782. doi:10.3389/fcimb.2021.756782
   PubMed Web of Science ®Google Scholar
• Ahmadi M, Ranjbar R, Behzadi P, Mohammadian T. Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella pneumoniae. Expert Rev Anti Infect Ther. 2021;20(3):463–472. doi:10.1080/14787210.2022.1990040
   Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960. doi:10.1128/AAC.00296-11
   PubMed Web of Science ®Google Scholar
• Nguyen M, Joshi SG. Carbapenem resistance in acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. J Appl Microbiol. 2021;131(6):2715–2738. doi:10.1111/jam.15130
   PubMed Web of Science ®Google Scholar
• Behzadi P, Garcia-Perdomo HA, Karpinski TM, Issakhanian L. Metallo-ss-lactamases: a review. Mol Biol Rep. 2020;47(8):6281–6294. doi:10.1007/s11033-020-05651-9
   PubMed Web of Science ®Google Scholar
• Reyes J, Aguilar AC, Caicedo A. Carbapenem-resistant Klebsiella pneumoniae: microbiology key points for clinical practice. Int J Gen Med. 2019;12:437–446. doi:10.2147/IJGM.S214305
   PubMed Web of Science ®Google Scholar
• Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–272. doi:10.1016/j.molmed.2012.03.003
   PubMed Web of Science ®Google Scholar
• Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–1106. doi:10.1086/592412
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582. doi:10.1128/CMR.00058-07
   PubMed Web of Science ®Google Scholar
• Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423. doi:10.1111/1469-0691.12363
   PubMed Web of Science ®Google Scholar
• Catho G, Martischang R, Boroli F, et al. Outbreak of pseudomonas aeruginosa producing vim carbapenemase in an intensive care unit and its termination by implementation of waterless patient care. Crit Care. 2021;25(1):301. doi:10.1186/s13054-021-03726-y
   Web of Science ®Google Scholar
• Wei L, Wu L, Wen H, et al. Spread of carbapenem-resistant Klebsiella pneumoniae in an intensive care unit: a whole-genome sequence-based prospective observational study. Microbiol Spectr. 2021;9(1):e0005821. doi:10.1128/Spectrum.00058-21
   Web of Science ®Google Scholar
• Kim DH, Jung SI, Kwon KT, Ko KS. Occurrence of diverse abgri1-type genomic islands in acinetobacter baumannii global clone 2 isolates from South Korea. Antimicrob Agents Chemother. 2017;61(2). doi:10.1128/AAC.01972-16
   Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. 30th. In: CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020
   Google Scholar
• Hu H, Mao J, Chen Y, et al. Clinical and microbiological characteristics of community-onset carbapenem-resistant Enterobacteriaceae isolates. Infect Drug Resist. 2020;13:3131–3143. doi:10.2147/IDR.S260804
   PubMed Web of Science ®Google Scholar
• Seifert H, Dolzani L, Bressan R, et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of acinetobacter baumannii. J Clin Microbiol. 2005;43(9):4328–4335. doi:10.1128/JCM.43.9.4328-4335.2005
   PubMed Web of Science ®Google Scholar
• Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus acinetobacter). J Bacteriol. 1968;95(5):1520–1541. doi:10.1128/jb.95.5.1520-1541.1968
   Web of Science ®Google Scholar
• Lee CR, Lee JH, Park M, et al. Biology of acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55. doi:10.3389/fcimb.2017.00055
   PubMed Web of Science ®Google Scholar
• Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant acinetobacter baumannii and Enterobacteriaceae in south and Southeast Asia. Clin Microbiol Rev. 2017;30(1):1–22. doi:10.1128/CMR.masthead.30-1
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the who priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Bernards AT, Frenay HM, Lim BT, Hendriks WD, Dijkshoorn L, van Boven CP. Methicillin-resistant staphylococcus aureus and acinetobacter baumannii: an unexpected difference in epidemiologic behavior. Am J Infect Control. 1998;26(6):544–551. doi:10.1053/ic.1998.v26.a84555
   Web of Science ®Google Scholar
• Marti E, Variatza E, Balcazar JL. The role of aquatic ecosystems as reservoirs of antibiotic resistance. Trends Microbiol. 2014;22(1):36–41. doi:10.1016/j.tim.2013.11.001
   PubMed Web of Science ®Google Scholar
• Meschiari M, Lopez-Lozano JM, Di Pilato V, et al. A five-component infection control bundle to permanently eliminate a carbapenem-resistant acinetobacter baumannii spreading in an intensive care unit. Antimicrob Resist Infect Control. 2021;10(1):123. doi:10.1186/s13756-021-00990-z
   Web of Science ®Google Scholar
• Bian X, Liu X, Zhang X, et al. Epidemiological and genomic characteristics of acinetobacter baumannii from different infection sites using comparative genomics. BMC Genomics. 2021;22(1):530. doi:10.1186/s12864-021-07842-5
   PubMed Web of Science ®Google Scholar
• Jiang M, Liu L, Ma Y, et al. Molecular epidemiology of multi-drug resistant acinetobacter baumannii isolated in Shandong, China. Front Microbiol. 2016;7:1687. doi:10.3389/fmicb.2016.01687
   PubMed Web of Science ®Google Scholar
• Deng M, Zhu MH, Li JJ, et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother. 2014;58(1):297–303. doi:10.1128/AAC.01727-13
   Web of Science ®Google Scholar
• Chen Y, Gao J, Zhang H, Ying C. Spread of the blaoxa-23-containing tn2008 in carbapenem-resistant acinetobacter baumannii isolates grouped in cc92 from China. Front Microbiol. 2017;8:163. doi:10.3389/fmicb.2017.00163
   Web of Science ®Google Scholar
• Lerner A, Adler A, Abu-Hanna J, Meitus I, Navon-Venezia S, Carmeli Y. Environmental contamination by carbapenem-resistant Enterobacteriaceae. J Clin Microbiol. 2013;51(1):177–181. doi:10.1128/JCM.01992-12
   PubMed Web of Science ®Google Scholar
• Yan Z, Zhou Y, Du M, et al. Prospective investigation of carbapenem-resistant Klebsiella pneumonia transmission among the staff, environment and patients in five major intensive care units, Beijing. J Hosp Infect. 2019;101(2):150–157. doi:10.1016/j.jhin.2018.11.019
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter Baumannii and Pseudomonas Aeruginosa in Health Care Facilities. Geneva: World Health Organization; 2017.
   Google Scholar
• Di Tella D, Tamburro M, Guerrizio G, Fanelli I, Sammarco ML, Ripabelli G. Molecular epidemiological insights into colistin-resistant and carbapenemases-producing clinical Klebsiella pneumoniae isolates. Infect Drug Resist. 2019;12:3783–3795. doi:10.2147/IDR.S226416
   PubMed Web of Science ®Google Scholar
• Lomonaco S, Verghese B, Gerner-Smidt P, et al. Novel epidemic clones of listeria monocytogenes, United States, 2011. Emerg Infect Dis. 2013;19(1):147–150. doi:10.3201/eid1901.121167
   Web of Science ®Google Scholar
• Xu H, Zhang W, Zhang K, et al. Characterization of salmonella serotypes prevalent in asymptomatic people and patients. BMC Infect Dis. 2021;21(1):632. doi:10.1186/s12879-021-06340-z
   Web of Science ®Google Scholar
• Xu Q, Fu Y, Zhao F, Jiang Y, Yu Y. Molecular characterization of carbapenem-resistant serratia marcescens clinical isolates in a tertiary hospital in Hangzhou, China. Infect Drug Resist. 2020;13:999–1008. doi:10.2147/IDR.S243197
   Web of Science ®Google Scholar
• Markogiannakis A, Fildisis G, Tsiplakou S, et al. Cross-transmission of multidrug-resistant acinetobacter baumannii clonal strains causing episodes of sepsis in a trauma intensive care unit. Infect Control Hosp Epidemiol. 2008;29(5):410–417. doi:10.1086/533545
   Web of Science ®Google Scholar
• Wheatley R, Diaz CJ, Kapel N, et al. Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute pseudomonas aeruginosa infection. Nat Commun. 2021;12(1):2460. doi:10.1038/s41467-021-22814-9
   Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2):162. doi:10.3390/pharmaceutics13020162
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10). doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1):31. doi:10.3390/pharmaceutics14010031
   PubMed Web of Science ®Google Scholar
• Wanla W, Katip W, Supakul S, Apiwatnakorn P, Khamsarn S. Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation. Int J Gen Med. 2017;10:443–449. doi:10.2147/IJGM.S145133
   PubMed Web of Science ®Google Scholar
• Chen W. Host innate immune responses to acinetobacter baumannii infection. Front Cell Infect Microbiol. 2020;10:486. doi:10.3389/fcimb.2020.00486
   PubMed Web of Science ®Google Scholar